Telaprevir/boceprevir Era: from Bench to Bed and Back

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2012 Nov 28

PMID 23180937

Citations 13

Authors

Qiuwei Pan

Maikel P Peppelenbosch

Harry L A Janssen

Robert J de Knegt

Affiliations

Soon will be listed here.

Abstract

Hepatitis C virus (HCV) infects approximately 200 million people worldwide. Interferon-based therapies have dominated over the past two decades. However, the overall response rates remain suboptimal. Thanks to the tremendous effort from both academia and industry, two serine protease inhibitors telaprevir and boceprevir for treating chronic hepatitis C have finally reached the clinic. Although these compounds are only approved for combination use with interferon and ribavirin in genotype 1 HCV infected chronic patients, the management of HCV patients however is now evolving incredibly. Here, we overviewed a series of landmark studies, regarding the clinical development of telaprevir and boceprevir. We discussed the mechanism-of-action of telaprevir/boceprevir and their potential application in HCV-positive liver transplantation patients. We further emphasized some emerging concerns with perspective of further development in this field.

Citing Articles

Development of ketobenzothiazole-based peptidomimetic TMPRSS13 inhibitors with low nanomolar potency.

Joushomme A, Desilets A, Champagne W, Hassanzadeh M, Lemieux G, Gravel-Trudeau A J Enzyme Inhib Med Chem. 2025; 40(1):2466841.

PMID: 39976239 PMC: 11843629. DOI: 10.1080/14756366.2025.2466841.

Development of ketobenzothiazole-based peptidomimetic TMPRSS13 inhibitors with low nanomolar potency.

Joushomme A, Desilets A, Champagne W, Hassanzadeh M, Lemieux G, Gravel-Trudeau A bioRxiv. 2024; .

PMID: 39257753 PMC: 11383682. DOI: 10.1101/2024.08.28.609965.

Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.

Sallam M, Khalil R Microorganisms. 2024; 12(6).

PMID: 38930417 PMC: 11205832. DOI: 10.3390/microorganisms12061035.

A Computational Study of Phenothiazine Derivatives as Acetylcholinesterase Inhibitors Targeting Alzheimer's Disease.

Prema V, V P, Meena A, A P, Ramalakshmi N, N P Cent Nerv Syst Agents Med Chem. 2024; 25(1):68-82.

PMID: 38757327 DOI: 10.2174/0118715249300784240430110628.

Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus.

Kamal S, Shahzad A, Rehman K, Tariq K, Akash M, Imran M Curr Med Chem. 2023; 31(15):2052-2072.

PMID: 37855348 DOI: 10.2174/0109298673234823230921090431.

References

Garg V, van Heeswijk R, Lee J, Alves K, Nadkarni P, Luo X . Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011; 54(1):20-7. DOI: 10.1002/hep.24443. View

Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J . Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2005; 44(1):97-103. DOI: 10.1016/j.jhep.2005.10.003. View

Pan Q, Tilanus H, Janssen H, van der Laan L . Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element. Hepatology. 2011; 53(4):1400-1. DOI: 10.1002/hep.24202. View

McHutchison J, Everson G, Gordon S, Jacobson I, Sulkowski M, Kauffman R . Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360(18):1827-38. DOI: 10.1056/NEJMoa0806104. View

Pan Q, Tilanus H, Metselaar H, Janssen H, van der Laan L . Virus-drug interactions--molecular insight into immunosuppression and HCV. Nat Rev Gastroenterol Hepatol. 2012; 9(6):355-62. PMC: 7097508. DOI: 10.1038/nrgastro.2012.67. View

Pan Q, de Ruiter P, Metselaar H, Kwekkeboom J, De Jonge J, Tilanus H . Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology. 2012; 55(6):1673-83. DOI: 10.1002/hep.25562. View

Perni R, Almquist S, Byrn R, Chandorkar G, Chaturvedi P, Courtney L . Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother. 2006; 50(3):899-909. PMC: 1426435. DOI: 10.1128/AAC.50.3.899-909.2006. View

Brown R . Hepatitis C and liver transplantation. Nature. 2005; 436(7053):973-8. DOI: 10.1038/nature04083. View

Thomas E, Feld J, Li Q, Hu Z, Fried M, Liang T . Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology. 2011; 53(1):32-41. PMC: 3498496. DOI: 10.1002/hep.23985. View

10.

Hess G . Treatment of chronic hepatitis C. J Hepatol. 1991; 13 Suppl 1:S17-20. DOI: 10.1016/0168-8278(91)91715-s. View

11.

Reesink H, Zeuzem S, Weegink C, Forestier N, van Vliet A, van de Wetering de Rooij J . Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006; 131(4):997-1002. DOI: 10.1053/j.gastro.2006.07.013. View

12.

Schaefer E, Chung R . Anti-hepatitis C virus drugs in development. Gastroenterology. 2012; 142(6):1340-1350.e1. DOI: 10.1053/j.gastro.2012.02.015. View

13.

Gottwein J, Scheel T, Jensen T, Ghanem L, Bukh J . Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology. 2011; 141(3):1067-79. DOI: 10.1053/j.gastro.2011.06.004. View

14.

Casey L, Lee W . Hepatitis C therapy update. Curr Opin Gastroenterol. 2012; 28(3):188-92. DOI: 10.1097/MOG.0b013e3283528e1e. View

15.

Berger A, Schechter I . Mapping the active site of papain with the aid of peptide substrates and inhibitors. Philos Trans R Soc Lond B Biol Sci. 1970; 257(813):249-64. DOI: 10.1098/rstb.1970.0024. View

16.

Bartenschlager R, Mous J, Jacobsen H . Kinetic and structural analyses of hepatitis C virus polyprotein processing. J Virol. 1994; 68(8):5045-55. PMC: 236447. DOI: 10.1128/JVI.68.8.5045-5055.1994. View

17.

Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie A, Reddy K, Bzowej N . Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405-16. DOI: 10.1056/NEJMoa1012912. View

18.

Malcolm B, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N . SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother. 2006; 50(3):1013-20. PMC: 1426438. DOI: 10.1128/AAC.50.3.1013-1020.2006. View

19.

Bruno S, Shiffman M, Roberts S, Gane E, Messinger D, Hadziyannis S . Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology. 2009; 51(2):388-97. DOI: 10.1002/hep.23340. View

20.

Welsch C, Jesudian A, Zeuzem S, Jacobson I . New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut. 2012; 61 Suppl 1:i36-46. DOI: 10.1136/gutjnl-2012-302144. View